Search

The article discusses the practicing rural social workers, with an exploratory factor analysis (EFA) of the index for training need (ITN). The analysis is conducted to examine the psychometric performance of a scale to asses the interest in specific addiction related training areas. It is said that EFA is the most appropriate statistical process to examine the validity of the content. Results show that 59 percent of the respondents do not feel their education prepared them for work with addicted populations.

The article presents the author's insights regarding the aspects of the craft of writing for young adults and children. Topics discussed include author Sara Pennypacker and her new novel "Pax," which is about the outcomes of war, author's approach to the challenge with healthy amount of fear and humility, as well as hope, and authors' satisfaction in writing.

Escitalopram, a selective serotonin reuptake inhibitor (SSRI) was recently approved by the United States Food and Drug Administration (FDA) for the treatment of major depression. This chapter reviews preclinical and clinical studies with escitalopram, focusing on its therapeutic profile of action and tolerability. Escitalopram is the S-enantiomer of the racemic SSRI citalopram. It has been proposed that the S-enantiomer of citalopram is the isomer that holds antidepressant efficacy, and that the R-enantiomer is clinically inactive; preclinical and clinical data support this. Based on in vitro radioligand binding data, escitalopram is the most selective SSRI available. Hypotheses that escitalopram has a more rapid onset of action or fewer adverse effects than citalopram have not yet been fully documented in published studies, although its profile is at least comparable to citalopram. Escitalopram is more effective than placebo in the treatment of major depression and as effective as other SSRIs, including citalopram. Comparable to other SSRIs, it is well tolerated, safe in overdose and has a low incidence of adverse effects or drug interactions., ((c) 2004 Prous Science. All rights reserved.)